382 related articles for article (PubMed ID: 26482681)
1. Bifidobacteria possess inhibitory activity against dipeptidyl peptidase-IV.
Zeng Z; Luo JY; Zuo FL; Yu R; Zhang Y; Ma HQ; Chen SW
Lett Appl Microbiol; 2016 Mar; 62(3):250-5. PubMed ID: 26482681
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the susceptibility of porcine and human dipeptidyl-peptidase IV to inhibition by protein-derived peptides.
Lacroix IM; Li-Chan EC
Peptides; 2015 Jul; 69():19-25. PubMed ID: 25828735
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Koska J; Sands M; Burciu C; Reaven P
Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
[TBL] [Abstract][Full Text] [Related]
5. A Novel Dipeptidyl Peptidase IV Inhibitory Tea Peptide Improves Pancreatic β-Cell Function and Reduces α-Cell Proliferation in Streptozotocin-Induced Diabetic Mice.
Lu Y; Lu P; Wang Y; Fang X; Wu J; Wang X
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646613
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer.
Almagthali AG; Alkhaldi EH; Alzahrani AS; Alghamdi AK; Alghamdi WY; Kabel AM
Diabetes Metab Syndr; 2019; 13(1):36-39. PubMed ID: 30641726
[TBL] [Abstract][Full Text] [Related]
8. Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes.
Power O; Nongonierma AB; Jakeman P; FitzGerald RJ
Proc Nutr Soc; 2014 Feb; 73(1):34-46. PubMed ID: 24131508
[TBL] [Abstract][Full Text] [Related]
9. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
[TBL] [Abstract][Full Text] [Related]
10. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: A Review.
Liu R; Cheng J; Wu H
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678216
[TBL] [Abstract][Full Text] [Related]
12. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
Singh AK; Jatwa R; Purohit A; Ram H
J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157
[TBL] [Abstract][Full Text] [Related]
13. Features of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides from dietary proteins.
Nongonierma AB; FitzGerald RJ
J Food Biochem; 2019 Jan; 43(1):e12451. PubMed ID: 31353485
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase IV inhibitory peptides generated in Spanish dry-cured ham.
Gallego M; Aristoy MC; Toldrá F
Meat Sci; 2014 Feb; 96(2 Pt A):757-61. PubMed ID: 24200567
[TBL] [Abstract][Full Text] [Related]
15. Investigation into the bioavailability of milk protein-derived peptides with dipeptidyl-peptidase IV inhibitory activity using Caco-2 cell monolayers.
Lacroix IME; Chen XM; Kitts DD; Li-Chan ECY
Food Funct; 2017 Feb; 8(2):701-709. PubMed ID: 28098291
[TBL] [Abstract][Full Text] [Related]
16. Identification of Potential Dipeptidyl Peptidase (DPP)-IV Inhibitors among
Yang Y; Shi CY; Xie J; Dai JH; He SL; Tian Y
Molecules; 2020 Jan; 25(1):. PubMed ID: 31906524
[No Abstract] [Full Text] [Related]
17. Physiology and pathophysiology of incretins in the kidney.
von Websky K; Reichetzeder C; Hocher B
Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.
Drucker DJ
Expert Opin Investig Drugs; 2003 Jan; 12(1):87-100. PubMed ID: 12517256
[TBL] [Abstract][Full Text] [Related]
19. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Green BD; Flatt PR; Bailey CJ
Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
